08:25 AM EDT, 07/14/2025 (MT Newswires) -- Iovance Biotherapeutics ( IOVA ) said Monday its drug Amtagvi led to a 48.8% objective response rate in a retrospective real-world study of 41 patients with skin cancer.

Patients treated earlier, after two or fewer prior therapies, saw a response rate of 60.9%, compared to 33.3% among those with three or more previous treatments, the company said.

All participants were treated at authorized centers under current US prescribing guidelines and received at least one follow-up physician assessment, Iovance said.

Shares of the company were up more than 4% in recent Monday premarket activity.

Price: 1.95, Change: +0.08, Percent Change: +4.28